{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Several ipynb files are creates to work on this project\n",
    "1. EDA.ipynb\n",
    "2. 01_getting_familiar.ipynb\n",
    "3. 02_data_preprocessing.ipynb and so on...\n",
    "\n",
    "### <strong> Problem Statement: Bankruptcy Prediction using Natural Language Processing </strong>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# <strong>Exploratory Data Analysis</strong>\n",
    "\n",
    "This notebook is dedicated to get familiar with the dataset we are using."
   ]
  },
  {
   "attachments": {
    "49d91b10-63f8-4a3a-bdfb-b7dc559dfa8c.png": {
     "image/png": "iVBORw0KGgoAAAANSUhEUgAAAW8AAACgCAYAAADD9e3BAAAAAXNSR0IArs4c6QAAAARnQU1BAACx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\nBTG8iYgUxPAmIlIO8P8gx38sBxrcAAAAAABJRU5ErkJggg==\n"
    }
   },
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "\n",
    "### <strong>Dataset</strong>\n",
    "We have a dataset with 2 different classes, Bankrupt and Healty companies, which contains scrapped MD&A section of companies of these class from their financial reports.\n",
    "\n",
    "File Structure of this dataset is as follow:\n",
    "\n",
    "<img src=\"Images/FileStructureofDataset.png\" width=auto>\n",
    "<!-- ![FileStructureofDataset.png](attachment:49d91b10-63f8-4a3a-bdfb-b7dc559dfa8c.png) -->\n",
    "\n",
    "There are 201 files in Bankrupt class and 298 in Healthy class."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "\n",
    "### <strong>Processing Textual Data</strong>\n",
    "Here we try to tokenize, lemmatize and remove the stopwords from the above dataset\n",
    "\n",
    "we need to perfom:\n",
    "* Tokenization\n",
    "* Lemmatiazation\n",
    "* Stopword Removal"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "# install dependicies\n",
    "!pip install spacy nltk matplotlib gensim textblob>> .installation_log.txt\n",
    "!python -m spacy download en_core_web_sm >> .installation_log.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# install models from nltk\n",
    "import nltk\n",
    "nltk.download('punkt', quiet=True)\n",
    "nltk.download('punkt_tab', quiet=True)\n",
    "nltk.download('vader_lexicon', quiet=True)\n",
    "nltk.download('stopwords', quiet=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# import and load all the required libraries and models to work on text data\n",
    "from nltk.corpus import stopwords\n",
    "from matplotlib import pyplot as plt\n",
    "import nltk\n",
    "import spacy\n",
    "\n",
    "nlp = spacy.load('en_core_web_sm')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def preprocess(text):\n",
    "    \"\"\"\n",
    "    Function to lemmatize and convert the text into small sentences(sentence tokenization)\n",
    "    \"\"\"\n",
    "    text = text.lower()\n",
    "    sentences = nltk.sent_tokenize(text)\n",
    "    print(\"sentence tokenization: \\n\", sentences)\n",
    "    \n",
    "    words = [nltk.word_tokenize(sent) for sent in sentences]\n",
    "    words = [[word.lower() for word in word_list if word.isalnum()] for word_list in words]\n",
    "    stop_words = set(stopwords.words('english'))\n",
    "    filtered_words = [[word for word in word_list if word not in stop_words] for word_list in words]\n",
    "    \n",
    "    lemmatized_words = []\n",
    "    for word_list in filtered_words:\n",
    "        doc = nlp(\" \".join(word_list))\n",
    "        lemmatized_words.append([token.lemma_ for token in doc])\n",
    "        \n",
    "    return lemmatized_words, sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "sentence tokenization: \n",
      " [\"abg shipyard limited\\nannual report 2012-2013\\n28\\nauditor's certificate on corporate governance\\nto the members,\\nabg shipyard limited.\", 'st \\nwe have examined the compliance of corporate governance by abg shipyard limited for the year ended on 31 march 2013, as \\nstipulated in clause 49 of the listing agreement of the said company with the stock exchanges.', 'the compliance of conditions of corporate governance is the responsibility of the management.', 'our examination has been limited \\nto a review of the procedures and implementations thereof adopted by the company for ensuring compliance with the conditions of \\nthe corporate governance as stipulated in the said clause.', 'it is neither an audit nor an expression of opinion on the financial \\nstatement of the company.', 'in our opinion and to the best of our information and according to the explanations given to us, and based on the representations \\nmade by the directors and the management, we certify that the company has complied with the conditions of corporate \\ngovernance as stipulated in clause 49 of the above mentioned listing agreement.', 'we state that such compliance is neither an assurance as to the future viability of the company, nor of the efficiency with which the \\nmanagement has conducted the affairs of the company.', 'for nisar & kumar\\nchartered accountants\\nf. r. no.', '107117w\\n      \\nm. n. ahmed\\nplace: mumbai\\n     (partner)\\nth\\ndate: 30  may, 2013\\n     m. no.', '18380\\nabg shipyard limited\\nannual report 2012-2013\\n29\\nannexure - c\\nmanagement discussion & analysis\\nmarket trends & economy\\nfinancial year 2012-13 is a challenging year to the global as well as indian economy.', 'world output was down from 4% in 2011 to \\n3.2% in 2012. emerging and developing economies output touched a low of 5.1%, reflecting a sharp drop from 6.4% in the previous \\nyear.', 'the u.s. economy improved marginally, driven mainly by housing and the consumer sectors; however, capital investments \\nremained sluggish.', 'the euro zone shrank by 0.6%.', 'among the asian economies, china, going through a political transition, \\nexperienced considerably slower growth.', 'during the financial year 2012-13, the indian economy experienced a low growth rate of about 5-5.5%.', 'year-on-year gdp growth \\nrd\\nrate, in the 3  quarter touched 4.5%, the second lowest in recent years.', 'industrial sectors, too, continued to reel under the severe \\nslowdown.', 'going ahead, most market analysts expect gdp to be around 6% in the financial year 2013-14, assuming a normal monsoon.', 'the \\nreserve bank of india remains focused on containing inflation, and is expected to continue following a conservative policy on \\ninterest rates.', 'sluggish value of indian rupees is also great concern to indian economy.', 'however, long term prospects for the indian economy, continue to remain bright, given the favorable demographics and the \\ndirectional commitment towards liberalization.', 'however, much work remains to be done to free up core sectors and restart growth.', 'outlook for the current fiscal with inflation now well within tolerance level, appears better than the previous year.', 'additionally, \\nsoftening of global commodity prices should help to reduce the imported inflation in domestic economy.', 'industry overview and outlook\\nglobally, shipbuilding and ship repair industry is growing at a compounded annual growth rate (cagr) of about 24 per cent and \\nis likely to reach ` 14 lakh crore by 2015 owing to rising global sea borne trade, according to the study done by the associate \\nchambers of commerce (assocham).', 'during the year under review, global shipbuilding industry experienced rapid decline in new shipbuilding orders as backlogs \\nremained high and the global economic downturn adversely affected the demand for new ships or vessels.', 'china, south korea and japan are leading shipbuilding nations and cater to over 80% of the global shipbuilding industry.', 'the \\nchinese government continues to give subsidies to the industry due to which the country enjoys over 35% of the global share.', 'the \\nchinese shipyards continue building ships which flood the market, depressing it further.', 'india and vietnam are seen as upcoming centers for global shipbuilding and have displayed enormous growth potential since 2000. \\nhowever, india has not yet reached a stage where it can enjoy economies of scale like korea or china.', 'still indian shipbuilding industry accounts for less than 1 percent of global market share.', 'according to study done by shipyards \\nassociation of india (sai), while shipbuilding in countries like china, south korea and japan continue to account for more than 80 \\nper cent of the global shipbuilding market.', 'the indian shipbuilding and ship repair industry is likely to reach ` 9,200 crore by year \\n2015, growing at a compounded annual growth rate (cagr) of about 8 per cent according to a study done by the  assocham.', 'on an average india produces around 20 ships in a year while developed shipbuilding markets make 70 -100 ships a year.', 'due to \\nthis, almost 90% of equipment for manufacturing ships is sourced from overseas.', 'with about an 8,000 kilometer  long coastline there are about 27 shipyards, 12 major ports and 200 ports under states jurisdiction in \\nindia.', 'approximately 90% of the countryâ€™s trade by volume and 70% by value are moved through maritime transport.', 'there is huge \\nscope for development of the shipping sector.', \"however, the country's opportunities in the maritime business have not been fully \\nutilized.\", 'an authentic estimate is  that the shipbuilding industry is likely to generate a revenue of ` 800 billion and an overall revenue of           \\n` 3300.00 billion including associated sectors.', 'employment to the extent of 0.4 million new direct jobs in shipbuilding and around 2.4 \\nmillion new jobs in shipbuilding, ship repairing and associated sectors can be generated.', 'the government has a key role to improve the efficiency and productivity of domestic shipbuilding companies to enable them to \\ncompete with their overseas counterparts.', 'the indian government has been very supportive in the past which gave a significant \\nfillip/ impetus to the industry.', 'although the government had extended the shipbuilding subsidy scheme from 2002 to 2007, which \\ncaused a temporary boom in the industry, however, the subsequent discontinuation of the scheme along with recession, had some \\nnegative impact on the industry.', 'various industrial bodies has recommend to revive of subsidy scheme, easing tax related \\nregulations and declaring shipbuilding a status of strategic industry.', 'the indian government has mooted plans to develop ancillary units for the shipbuilding sector, which has the potential to create \\napprox 2.4 million jobs.', 'the government has taken various initiatives for up - gradation of infrastructure in ports which include \\nexpeditious implementation of various capacity addition and mechanization project.', 'the initiatives include private sector \\nparticipation in capacity augmentation/ up-gradation for which bid documents have been standardized, and 100% fdi being allowed \\nunder the automatic route, income tax incentives are also available for investments made in port infrastructure.', 'opportunities & threats\\nunion budget 2013-14 has provided a slight relief to domestic shipbuilding industry by removing excise duty burden of 6% to the']\n",
      "\n",
      "sentence tokenization: \n",
      " ['our approach is to achieve more outcome with less\\nresources on every front of the wide operational landscape.', 'our strategy to focus on select, promising markets\\nglobally reflects this approach.', 'we set up a frontend in the lucrative us generic market five years ago.', 'since then, this business has grown considerably\\nand the future outlook is promising.', 'it is now one of\\nthe major growth engines of our company.', 'we wish\\nto offer a comprehensive range of products under\\ndermatology, oncology and ophthalmology therapies.', 'this business is focused on launching high potential,\\nhigh margin products to maximise existing and\\nemerging opportunities.', 'our superior customer advocacy, delivery and\\ncompliance mechanisms enable us to strengthen\\nour brand recall and deliver exceptional value.', 'consequently, within a short time span, we have built\\na loyal and growing base of customers.', 'managed by a\\ncohesive team of 10-12 people, this business is gaining\\nsignificant traction in the us.', 'revenues have touched\\nover $250 million in the past five years.', 'going forward,\\nwe are aiming to also specialise in injectables and are\\nfocusing on products having lower competition.', 'our strategy of allocating capital to grow the us\\ngenerics business has proved to be successful.', 'another instance of how we do more with less is to\\nidentify niche product opportunities such as sartans\\nto achieve a healthy balance between growth and\\nprofitability.', 'during 2019-20, we again demonstrated\\nour ability to maximise opportunities in a short period,\\nmore efficiently than our peers.', 'to summarise, this approach has paid off consistently\\nand enabled us to maintain a sound financial profile.', 'we have a successful track record of generating more\\nreturns, with fewer resources.', 'us generics sales\\n(h crores)\\nfy16 fy17 fy18 fy19 fy20 1,228 919 9201,288 1,976\\noncology injectable and osd plant\\nintroduction mda strategic review governance and social responsibility statutory reports financial statements\\nannual report 2019-20 17\\nconcentrated.', 'diversified.', 'opportunity landscape\\nof our key products is\\nsignificant in select,\\nconcentrated markets\\nour products cater to\\n10 therapies\\n18 alembic pharmaceuticals limited\\nover the past few years, we have diversified from oral solids to develop\\nproducts across different dosage forms such as injectables.', 'our product suite is well diversified across dosage\\nforms, branded, generic and the therapies they cater to.', 'similarly, we have ventured into different international\\nmarkets holding immense future potential.', 'yet, we have put in concentrated efforts on select\\nproducts such as anti-depressant drug, venlafaxine to\\nmark our presence globally and generate suatinable\\nreturns with a diversified portfolio.', 'another product offering significant growth\\nopportunities is azithromycin, an antibiotic for\\nbacterial infections.', 'in india, we are one of the\\nlargest manufacturers of azithromycin, with a\\n30% market share in india.', 'amid rising demand for\\nthe product, we have ramped up our production\\ncapacity for azithromycin.', 'this ramp-up is both for\\nthe domestic as well as international markets.', 'the\\ndemand for azithromycin has shot up significantly as\\nit is being tried to treat coronavirus in combination\\nwith hydroxychloroquine in the us and several\\nparts of europe.', 'we have secured final approval from the usfda\\nto launch azithromycin in the us in january 2020\\nand have recently lauched the product in the us.', 'azithromycin tablets have an estimated market size of\\n$129 million for 12 months ended september 2019\\naccording to iqvia.', 'thus, the fine balance between diversity in portfolio\\nand concentrated initiatives on select market segments\\nhold us in good stead.', 'we will continue to strengthen\\nthis balance, going forward.', 'formulation plant (f1), panelav\\nintroduction mda strategic review governance and social responsibility statutory reports financial statements\\nannual report 2019-20 19\\npeople driven.', 'process driven.', 'superlative performance\\nenabled us to file 25\\nandas per year, owing\\nto quality talent and\\nautonomy\\nrobust plant sops have\\nensured successful\\ncompletion of audits\\nwithout major 483â€™s\\nconsistently over years\\n20 alembic pharmaceuticals limited\\nwe believe empathetic, need-based people practices and efficient\\nprocesses go hand in hand and are crucial growth enablers.', 'our people policies span the entire spectrum of hiring\\nthe right talent, upskilling them, and motivating them to\\nput their best foot forward, every day.', 'we provide our\\npeople an enabling work environment that encourages\\nengagement, sharing of knowledge, concerns and\\nwhere the cross-pollination of ideas can always bloom.', 'to take a specific example, our us team is committed\\nand stable, and our overall attrition rate has declined\\nover the years.', 'our team in india has also grown over\\nthe years, and are meeting global benchmarks.', 'our\\nwell-articulated people policies and procedures play\\nan important role in making us one of the preferred\\nemployers in the pharmaceutical sector.', 'our team of about 11,500 people know that constant\\nadaptation, rapid learning, unlearning and relearning\\ncan only take us forward in a dynamic operating\\nenvironment.', 'this is where our robust processes come\\ninto the picture.', 'these processes straddle multiple\\nroutine and non-routine activities including efficient\\nâ€˜change managementâ€™ in the organisation.', 'our processes strengthen all our functions and help\\nus to be future-ready.', 'for instance, our consistent r&d\\ninitiatives have helped accelerate the pace of anda\\nfilings over the past five years.', 'the launch of new, and\\nrelevant products and therapies across markets will be\\none of our key growth catalysts.', 'this prudence in processes is also reflected in our\\noverall financial strategy.', 'we have accomplished some\\nof the industry-leading return ratios, margins and have\\namong the lowest receivables in the industry.', 'our debt\\nlevels are also contained below 1x and we are planning\\nto deleverage our balance sheet in future.', 'at alembic, quality is an absolute non-negotiable.', 'the integrated nature of our plant standard\\noperating procedures ensure that we maintain\\nhighest compliance standards.', 'the result is that\\nwe are among the few companies in the indian\\npharmaceutical industry to have clean status for our\\nusfda plants.', 'a case in point is our aleor plant which\\nwas cleared with zero observations and f1 plant with\\nminor observations.', 'introduction mda strategic review governance and social responsibility statutory reports financial statements\\nannual report 2019-20 21\\ntoday.', 'tomorrow.', 'delivered\\nhighest-ever\\nconsistent investment\\nin future revenue\\ngenerating streams viz\\nnew plants, new therapies,\\nr&d capabilities and\\npartnerships\\nrevenues\\nprofits\\n22 alembic pharmaceuticals limited\\nour success is defined equally by our achievements\\ntoday and our futuristic thinking to prepare for the\\nemerging opportunities and risks.', 'on one hand, we\\nare closely connected with the ground realities in our\\nbusiness segments and have a demonstrated ability to\\nidentify and maximise short-term opportunities.', 'on the other hand, we are making investments to\\naugment our capabilities in r&d, manufacturing,\\npeople and processes and capture the mediumto-long-term growth opportunities across our key\\nmarkets.', 'simultaneously, we have put in place a robust\\nand efficient risk management system to ensure\\nthat risks are kept within reasonable limits and any\\nsignificant impact on our operations and financials is\\nmitigated in the best possible manner.', 'our financial performance enables us to generate\\ngrowth capital, which is invested back in our plants,\\nproducts, therapies and strategic partnerships.', 'thus,\\nstaying strong today is a pre-requisite for us to become\\na better company tomorrow.', 'for us, at alembic, improvement in operational\\nefficiencies is an on-going process.', 'one example of\\nthis can be found in the way we manage our r&d\\nfunction.', 'we proactively scan our r&d grid to realign\\nour product portfolio by mapping it with critical factors\\nsuch as potential to garner desired market share and\\ngenerate profits.', 'products that donâ€™t fit the criteria are\\ndropped from the grid.', 'thus, we ensure that our r&d\\nefforts are moving in the right direction.', 'the us front-end is a credible example to demonstrate\\nhow we are optimising both short-term and long-term\\nopportunities.', 'with our unwavering focus on quality\\nand customer-service, we have managed to build a\\nloyal customer base in a short span of time.', 'close\\ncustomer relationships have helped us to ensure we\\nwere key beneficiary of supply disruptions, despite\\nhaving less than five years of us front-end experience.', 'our focus is on closing near-term, high-margin deals\\nand also reaching out for new customers.', 'this strategy\\nhas worked well for us.', 'in fact, we are among the few\\nindian companies to do well in both the us as well as\\ndomestic markets.', 'this fact is significant, especially at\\na time when many of our peers are slowly withdrawing\\nfrom the us generics market to expand in the\\ndomestic market.', 'general injectable and ophthalmic plant (f3)\\nintroduction mda strategic review governance and social responsibility statutory reports financial statements\\nannual report 2019-20 23\\nconsistent adaptation is progress\\noperational review: international generics\\nour international generics\\nbusiness span usa, canada,\\neurope, australia, south\\nafrica and brazil.', 'in recent\\nyears, we have undertaken\\ncapacity expansion to build\\nmanufacturing capabilities\\nto cater to these markets.', 'these markets have their\\nunique opportunities and\\nchallenges, which we\\nmanage with prudence.', 'simultaneously, we\\nhave stepped up our\\nr&d spends to build a\\npipeline of future-ready\\nproducts.', 'we endeavour\\nto grow in dermatology,\\nophthalmology, oncology\\nand injectable formulations.', 'key highlights of 2019-20\\n this business contributed 54%\\nto our total revenues in the year.', 'revenues from this business\\ngrew 39% to `2,473 crores from\\n`1,782 crores in 2018-19. an\\nexemplary performance from our\\nus front end led this performance.', 'revenues from this business\\nstood at `1,976 crores during the\\nyear â€“ contributing 43% to our\\noverall revenues and 80% to the\\ninternational generics business.', 'our us revenue grew 53% from\\n`1,288 crores in 2018-19.\\n excluding us, this business\\nremained flattish during the year\\nwith revenues of `497 crores visã\\xa0-vis `494 crores in 2018-19. the\\nperformance of this business was\\ndriven by new product launches,\\nstrategic partnerships and solid\\nrelationships with customers.', 'we have completed a large part\\nof our capex during the year and\\nare looking forward to tap the\\nopportunities in the segments\\nof ophthalmology, general\\ninjectables, oncology injectables\\nand oral solids.', 'we maintained strong compliance\\nas the aleor derma facility at\\nkarkhadi, which was audited by the\\nusfda without any observations.', 'while the formulation oral solids\\nfacility (f1) at panelav received\\nfour observations post inspection\\nof the usfda, the same were\\nprocedural in nature.', 'we launched 22 new\\nproducts in us as against nine\\nproducts in 2018-19 and will\\nbe ramping up new product\\nlaunches in the future.', 'new oral solid plant (f4)\\n24 alembic pharmaceuticals limited\\nupdate on rhizen\\npharmaceuticals\\n rhizen pharmaceuticals sa, of\\nwhich we own 50% equity will\\nstart contributing meaningfully\\nin 2020-21 with first out-licensed\\nproduct expected to be filed during\\nthe year.', 'rhizen had entered into an outlicensing agreement for tgr-1202\\n(umbralisib) with tg therapeutics\\nin september 2014.\\n tg therapeutics is expected\\nto complete the submission\\nof an nda for umbralisib for\\nmarginal zone lymphoma (mzl)\\nand follicular lymphoma (fl)\\nindications by 2020-21.\\n tg therapeutics announced\\npositive results from the phase\\n3 trial evaluating umbralisib\\nand ublituximab for chronic\\nlymphocytic leukemia (cll) with\\na filing expected in 2020-21.\\nrisks and challenges\\nhigh competitive intensity is a key risk for us.', 'driving operational efficiencies by building better\\nsupply chains has become a key focus area for us.', 'this business is vulnerable to risks arising out of\\ncurrency movements, regulatory changes and\\ngeo-political events.', 'api 1, panelav\\ninternational generics sales\\n(h crores)\\nfy16 fy17 fy18 fy19 fy20 1,461 1,236 1,2061,782 2,473\\n rhizen pharmaceuticals is eligible\\nto receive milestone payments\\nfor filing, approval and launch\\nof product and then salesbased royalties.', 'future priorities\\nwe are looking to launch new and distinct products\\nacross all our markets and enhancing the value\\nproposition of existing products.', 'our focus is\\non developing complex, niche products having\\nlimited competition.', 'we are making the requisite investments to strengthen\\nour workforce, upskill them and welcome new\\nrecruits.', 'this is in sync with our plans to expand\\ncapacities and cater to the growing demand.', 'we have a prudent hedge policy in place to\\nmanage this risk.', 'introduction mda strategic review governance and social responsibility statutory reports financial statements\\nannual report 2019-20 25\\ngrowing with clarity and courage\\noperational review: domestic branded business\\nthis business comprises branded and generic formulations with leading market\\nshare in multiple therapies including cardiology, anti-diabetic, gynaecology,\\ngastrology, dermatology, orthopaedic, ophthalmology, nephro / uro, anti-infective\\nand cold & cough.', 'key highlights of 2019-20\\n this business contributed 31% to\\nour full year revenues and grew a\\nmuted 3% to rs.', '1,425 crores from\\nrs.', '1,382 crores in 2018-19.\\n chronic therapies account for 65%\\nof domestic revenue and 93% of\\nnew launches in the last five years.', 'acute portfolio (cough & cold,\\npain management and antiinfectives) fairly resilient in the face\\nof current disruption.', 'benefits of the portfolio\\nand incentive rationalisation\\nexercise expected to be visible\\nstarting 2020-21.\\n per capita sales per month is low\\nfor us and this gives us significant\\nscope for improvement in mr\\nproductivity.', 'this will be visible in\\n2020-21 and onwards.', 'this weakness was on account\\nof the realignment we undertook\\nover the past three quarters.', 'post this strategic re-alignment,\\nour portfolio now comprises\\nhigh growth molecules and\\nbrands across acute and\\nchronic therapies.', 'withdrawal of stockist promotions\\nand inventory adjustments initiated\\ntowards the end of 2018-19\\nwill help improve supply chain\\nhygiene henceforth.', 'impact of the lockdown\\nimposed to contain the spread\\nof coronavirus was neutral\\non our business.', 'the business recovered in the\\nlast quarter of 2019-20 and\\nwe expect this momentum to\\ncontinue going forward.', 'the domestic market is growing at\\na healthy pace and we expect to\\ngrow at industry levels in 2020-21.\\n our strong field force, association\\nwith doctors and right product\\nlaunches are some of the key\\nenablers for this business.', 'research and development center, vadodara\\n26 alembic pharmaceuticals limited\\nformulation plant, sikkim\\nrisks and challenges\\ninconsistent implementation of the drug price\\ncontrol policy in india.', 'prices of drugs in the\\nnational list of essential medicines (nlem) are\\ndecided by the government on its own, without\\nany industry representation.', 'amid high competitive intensity, we have to\\nconstantly enhance our reach and manage our\\nsupply chain to ensure availability of our products\\nacross the country.', 'future priorities\\nwe strive to provide high quality, highly efficient\\nproducts at affordable rates to meet the medical\\nneeds of the indian population.', 'we are looking\\nto build our portfolio of specialty products to\\ndrive future growth.', 'adding new customers and creating better value for\\nthe existing ones is a key priority for us.', 'we also aim to improve the productivity of our field\\nforce to further expand the customer base and make\\nour products more accessible.', 'domestic branded sales\\n(h crores)\\nfy16 fy17 fy18 fy19 fy20 1,176 1,255 1,274 1,382 1,425\\nintroduction mda strategic review governance and social responsibility statutory reports financial statements\\nannual report 2019-20 27\\nsound foundation to\\ncreate value\\nfinancial review\\nour consolidated revenue for the\\nfull year stood at `4,606 crores, up\\n17%, compared to `3,935 crores in\\nfy19 with a 10-year cagr growth\\nof 15%.', 'our consolidated pat grew\\nat a faster pace than the revenues.', 'this metric grew by 42% to `829\\ncrores from `584 crores in fy19.', 'the 10-year cagr for pat stood at\\n36%.', 'our ebitda recorded a 10-year\\ncagr of 26% to reach `1,213 crores\\nin fy20 from `875 crores in fy19.', 'we\\nwere able to drive higher operational\\nefficiencies by addressing bottlenecks\\nacross our operations.', 'this, along\\nwith rising share of high-margin\\nproducts in our portfolio have aided\\noverall profitability.', 'we continued to create value for\\nour shareholders through capital\\nappreciation as well as by paying\\ndividends consistently.', 'as on march\\n31, 2020, our market capitalisation\\nwas `10,071.46 crores and we paid\\nan interim dividend of `7.0 per equity\\nshare and additional special dividend\\nof `3.0 per share (totaling 500%) on a\\nface value of `2 per equity share.', 'in\\n2018-19, we had paid a dividend of\\n`5.5 per equity share (275%).', '2019-20 was a remarkable year for us wherein we recorded the\\nhighest-ever revenue as well as net profit in our history.', 'us generics\\nbusiness was at the forefront of growth as we demonstrated, once again,\\nour ability to capture realisable opportunities in an agile yet efficient manner.', 'we incurred capex of `697 crores\\nin 2019-20 and with this, a large part\\nof the capital expenditure is behind\\nus.', 'in 2020-21, our capex is likely to\\npeak out at `700 crores per annum\\nand from 2021-22 will normalise to\\n`300-350 crores.', 'while our debt to\\nequity (net) inched up to 0.52x in\\n2019-20 from 0.34x in 2018-19, it will\\ncome down once new investments\\nstarts generating revenues from\\n2021-22. thus, we are aiming to\\nfurther strengthen our balance sheet\\nas well as cashflows over the next\\ncouple of years.', 'research and development center, new jersey\\n28 alembic pharmaceuticals limited\\ncfoâ€™s commentary\\nthe strong traction in the us market\\npowered our performance in\\n2019-20. this performance is an\\noutcome of our futuristic approach,\\nrobust execution capabilities,\\nagility of our supply chain, superior\\ncompliance record and best-in-class\\nservice offerings.', 'our domestic\\nbusiness gathered momentum\\nby the end of the year, despite\\nremaining weak in the first three\\nquarters.', 'our non-us markets\\nregistered uninspiring growth\\nowing to the implementation of\\nserialisation at plant.', 'during the year, we continued\\nto eliminate redundancies and\\nbottlenecks in our processes\\nacross all facilities.', 'concurrently,\\nwe continued to make the requisite\\ninvestments in r&d and capacity\\nexpansions to leverage future\\nopportunities.', 'as we strengthened\\nour capabilities to manufacture a\\ndiverse range of products, we expect\\nto garner additional market share\\nacross all our business segments.', 'we follow a disciplined approach\\nwhile managing our financials.', 'new product launches will drive\\nperformance of the us markets\\nand the domestic market offers\\nsignificant potential to generate\\nhigher cashflows and attractive\\nreturn ratios on the back of relatively\\nlower investments.', 'once commissioned, our enhanced\\ncapacities will be adequate to drive\\nour growth over the ensuing three\\nto four years.', 'as capital investment\\ndeclines post 2020-21, we will\\nwitness higher cashflow generation\\nand more attractive return ratios.', 'cashflows so freed up will be used\\nto de-leverage our balance sheet to\\nmaintain optimum debt.', 'as expected,\\nwe continue to receive high credit\\nrating of aa+ (stable) by crisil while\\nraising long-term debt and a1+ by\\ncrisil for short-term debt.', 'high\\ninvestment grade helps us restrict\\nour cost of funds.', 'a robust financial\\nstrategy remains an important\\npriority for us.', 'best regards,\\nraj kumar baheti\\ndirector â€“ finance and cfo\\nintroduction mda strategic review governance and social responsibility statutory reports financial statements\\nannual report 2019-20 29\\nwell-prepared to combat\\nchallenges\\nrisk management\\nquality risk\\nin case of discrepancies during packaging/\\nmanufacturing, adverse event may occur due to\\nfailure of collection, review, follow up, or report\\nadverse events from all potential sources.', 'principal risks mitigation strategy\\ncompetitive dynamics\\nadverse global and domestic demandsupplydynamics and unfair trade practices\\ncan pose competitive risks.', 'regulatory & compliance\\nan unfavourable facility inspection from any\\nmajor regulatory body, leading to significant\\ndelay of product exports.', 'currency risk\\nour expenses and investments are primarily in\\nindian currency.', 'however, revenues are spread\\nout across various international currencies.', 'therefore, our income may be vulnerable to\\nfluctuations in exchange rates.', 'environment, health, safety and\\nsustainability\\nany shortcoming in compliance with company\\npolicies on maintaining environment, health,\\nsafety and sustainability standards can erode\\nthe brand image and trust.', 'constant quality enhancements across plants to\\ncomply with international standards\\n improvements incorporated throughout the\\norganisation and team committed to quality\\nstandards and procedures\\n continuously monitor and evaluate the market\\ndevelopments and competitive landscape\\n nimble supply chain to ensure products being\\ndelivered at the place of demand always in time\\n established a strong team of experts with\\ndomain expertise\\n robust quality system across the organisation to\\nensure complete compliance\\neffective training to all technical personnel\\n 24x7 audit preparedness as a result of\\nfrequent mock audits\\n established robust currency hedging strategy and\\nexecution capabilities to safeguard ourselves\\n greater focus and increased regulatory activity on\\nenvironmental issues\\n stringent controls and governance framework\\nenabling compliance\\n30 alembic pharmaceuticals limited\\ntemporary delay\\nany delay in approval of new plants will lead to\\ndelay in launch of new products, resulting in\\nrevenue and opportunity loss.', 'cyber security\\ndata protection is of utmost importance\\nand lack of which can lead to tangible and\\nintangible losses.', 'intellectual property\\nthe company may run the risk of running into\\nlitigation if companyâ€™s products and processes\\ninfringe patent held by other manufacturers.', 'stringent monitoring of new plant activities for\\ntimely commissioning and completion of audits\\n built strong r&d expertise to leverage\\nmanufacturing opportunities on receiving approvals\\n strong cyber security infrastructure with a robust data\\nprotection policy\\n constant investment in upgrading skills of\\nmanpower and systems\\n created a vigilance mechanism via an ipr\\ndepartment to check for possible infringement\\nof intellectual property rights of patent\\nholders/innovators\\nat alembic, we maintain a system\\nof well-established policies and\\nprocedures for internal control\\nof operations and activities.', 'we\\ncontinuously strive to integrate the\\nentire organisation from strategic\\nsupport functions like finance, human\\nresources, and regulatory affairs\\nto core operations like research,\\nmanufacturing and supply chain.', 'the internal audit function is further\\nstrengthened in consultation with\\nstatutory auditors for monitoring\\nstatutory and operational issues.', 'adherence to statutory compliance is\\na key focus area for entire leadership\\nteam of the company.', 'we had appointed ernst & young, llp,\\nas internal auditors with the prime\\nobjective of testing the adequacy and\\neffectiveness of all internal control\\nsystems and suggest improvements.', 'significant issues are brought to the\\nattention of the audit committee for\\nperiodical review.', 'the enterprisewide risk evaluation and validation\\nprocess is carried out by the risk\\nmanagement committee and the\\nboard of directors.', 'to set the tone for the company\\nto attain effective and efficient\\ninternal control and documentation,\\nwe have already institutionalised a\\ndocument management system for\\nboth core and strategic operations.', 'moreover, the company has\\nobtained iso 9001 and iso 14001\\ncertifications and adheres to the\\nstandard operating procedures\\nrelevant to our manufacturing and\\noperating activities.', 'internal control systems and their adequacy\\nintroduction mda strategic review governance and social responsibility statutory reports financial statements\\nannual report 2019-20 31\\ntrends shaping our future\\nexternal environment\\nthe world around us is becoming increasingly unpredictable and volatile.', 'we keep\\na close watch on the emerging realities in our external environment.', 'the trends\\nand the way we respond to them broadly shape our long-term ability to create\\nand retain value.', 'economic uncertainty\\nas estimated by imf, global economy grew by 2.9% in 2019,\\ndown 70 basis points over the growth witnessed in 2018.\\nhowever, post the spread of coronavirus pandemic in 2020,\\nthe imf expects the world economy to slip into recession and\\ndecline by 3% in 2020. indian economy, however, is likely to\\ndo better than the rest.', 'imf estimates indian economy to grow\\nby 1.9% in fy20.', 'in 2021, though the situation is expected to\\nnormalise with world economy likely to grow by 5.8% and indian\\neconomic growth pegged at 7.4%.', 'there could be a temporary\\nweakness in non-critical treatments.', '3.6\\n-3.0\\n2.9\\n5.8\\nglobal growth (gdp) trend (%)\\n2018\\n2020 (p) 2021 (p)\\n2018\\nsource: imf world economic outlook, april 2020\\np: projections\\napi plant, karkhadi\\n32 alembic pharmaceuticals limited\\ndemographic shifts\\nfrom 7.8 billion in may 2020, global population is projected to\\nreach 8.5 billion in 2030 and 9.7 billion in 2050 (source: united\\nnations).', 'while africa will be the largest contributor to this\\ngrowth, asia will be the second (with china and india being the\\nmost populated countries).', 'part of the increase in population will\\nbe on account of improving life expectancy rates.', 'this, along\\nwith weakening fertility rates could lead to higher proportion\\nof ageing population around the world.', 'it is expected that the\\nnumber of people aged 80 or above could increase by over\\nthree times to 425 million globally between 2017 and 2050. thus,\\nspends on medicines are likely to stay strong in the future.', 'serialisation\\nrequirements\\nto combat the menace of counterfeit\\nmedicines, the eu region introduced\\na serialisation policy in february\\n2019. the policy involves multiple\\nchanges to manufacturing and\\noverall distribution systems and\\nentails significant investments in\\nrequisite technology by pharma\\ncompanies.', 'while this is a step in\\nthe right direction, it had an impact\\non eu pharma markets during\\n2019-20. even as the situation has\\nnormalised currently, other markets\\nin the world are also likely to\\nimplement such norms.', 'growing pressure\\non pricing\\nover the past few years, there has\\nbeen an increase in the demand for\\nquality medicines and healthcare\\nfacilities at reasonable rates.', 'many\\ncountries have introduced measures\\nto regulate the prices of medicines\\nand make them more accessible to\\nall sections of the society.', 'in india\\nas well, prices of 851 medicines are\\nregulated under the government\\nof indiaâ€™s national list of essential\\nmedicines, 2015. pharma companies\\naround the world are aligning\\ntheir cost structures to meet\\nthese requirements and maximise\\nthis opportunity.', 'prevalence of\\nchronic diseases\\nsignificant changes in lifestyle and\\nfood habits of people in recent times\\nhave led to a rapid increase in cases\\nof chronic diseases across large parts\\nof the world.', 'obesity, cardiovascular\\ndiseases, hypertension and diabetes\\nare common diseases in many\\ndeveloping and developed countries.', 'this trend is likely to continue\\nand will exert higher pressure on\\ngovernments and public health\\nsystems globally to provide requisite\\nmedicines and affordable treatments\\nfor these diseases.', '5.3\\n9.7\\n7.3 8.5\\n11.2\\nworld population (in billion)\\n1990\\n2050 (p) 2100 (p)\\n2030 (p)\\n2015\\nsource: https://www.un.org/en/sections/issues-depth/population/\\np: projections\\nintroduction mda strategic review governance and social responsibility statutory reports financial statements\\nannual report 2019-20 33\\npillars that underpin consistent\\nperformance\\nstrategic enablers\\nour mission â€˜to improve healthcare with innovation, commitment & trustâ€™ shapes\\neverything that we do.', 'the four pillars of quality, capability, customer centricity and\\ndiversity are the key enablers for our future growth.', 'quality\\nmaintaining quality is paramount\\nin our operational ecosystem to\\nbe able to deliver consistently and\\nretain our brand reputation.', 'our\\nmanagement helps ensure complete\\ncompliance with regulations.', 'it is\\nour constant endeavour to push the\\nbar higher for quality excellence.', 'inspired by our leadership, every\\nmember of our team has embraced a\\nculture of quality.', 'we follow a two-pronged\\napproach towards quality\\ncontrol with an emphasis on\\nstrengthening our people and\\nmanufacturing capabilities.', 'enhancing our\\npeople capabilities\\nat alembic, learning and\\ndevelopment is an ongoing\\nprocess.', 'we conduct varied training\\nprogrammes for our people working\\nacross functions to upskill them\\nabout our quality processes.', 'through\\nour training lab, we create awareness\\nabout good manufacturing\\npractices (gmp) among our teams.', 'trainings also cover topics such\\nas maintaining documentation,\\nproviding need-based technical\\ntrainings on equipment/machines\\nand so on.', 'we engaged with external\\nagencies like national science\\nfoundation (nsf) to train our middle\\nmanagement on critical topics such\\nas compliance.', 'these initiatives have\\nboosted employee confidence and\\nour employee retention rates have\\nspiralled up over the past few years.', 'upgrading our\\nmanufacturing capabilities\\nwe continue to embrace technology\\nand upgrade our facilities with the\\nobjective of enhancing the quality of\\nour products as well as processes.', 'some of the important initiatives\\nimplemented in recent years include\\nadoption of laboratory information\\nmanagement system (lims) in our\\nplants (ensure seamless workflow and\\ndata tracking) and quality by design\\n(qbd) initiative to enhance the\\nsafety and efficacy of our products.', 'at alembic, we strive to improve\\nquality of our products continuously\\nand thereby, create superior value\\nfor our customers.', '34 alembic pharmaceuticals limited\\ncapability\\nmajor capacity expansion\\nnearing completion\\nwe are on track to finish our large\\ncapex projects worth `2,000 crores\\nin 2020-21. post this capacity\\nexpansion, we will have enhanced\\nnew dosage offerings and will be\\nable to cater to the strong demand\\nin us generics segment.', 'benefits\\nfrom these expansions are likely\\nto start from 2021-22. our focus\\nis on ramping up filings across\\nophthalmology, general injectables,\\noncology injectables and oral solids.', 'our emphasis is on strengthening\\ncapacities and growing our product\\nportfolio to meet emerging and\\nexisting needs of patients.', 'r&d capabilities\\n our unwavering focus on\\ndeveloping innovative solutions\\nto meet patient needs around\\nthe world lends us a distinct,\\nsustainable competitive edge.', 'our team of about 1,200 r&d\\nemployees with diverse skill sets\\nare working relentlessly to enable\\nus to accelerate the pace of filings.', 'r&d as a % of revenue has\\nincreased from 6.7% in 2014-15\\nto 14% in 2019-20. we are able\\nto generate windfall gains from\\nproduct- specific opportunities\\nbecause of these concentrated\\nefforts.', 'we have reinvested gains\\nfor sustainable growth.', '90% of our r&d spends are\\ndirected towards the high growth\\nus market.', 'we continued to\\ninvest in r&d against the run of\\nplay with several generic players\\ndownsizing their us investments.', 'this contararian approach has\\npaid rich dividend.', 'we have adopted a prudent\\nstrategy involving a mix of low-risk\\nand high-risk para iv filings.', 'several filters are implemented\\nbefore taking a product in the\\nr&d grid with large crossfunctional teams required to\\nvalidate the decision.', 'with injectables and complex\\ngenerics in the pipeline, r&d\\ninvestments are expected to\\nstart yielding dividends from\\n2021-22 onwards.', 'we are providing products in\\ndifferent dosage forms across\\nseveral therapies to maximise\\nthe opportunities across\\nall our markets.', 'international generics\\nlocation dosage form audit/filing status\\nupdate on audit/filing status\\napi\\nf1-panelav\\nf2-panelav\\nf3-karkhadi\\nf4-jarod\\naleor (jv) karkhadi\\napi i & ii-panelav\\napi iii-karkhadi\\ngeneral oral solids\\noncology oral solids\\noncology injectables\\ngeneral injectables ophthalmic\\ngeneral oral solids\\nvarious derma forms\\nmarch 2020#\\njune 2019#\\nh2fy21##\\njanuary 2020##\\nh1fy21##\\njanuary 2020#\\ndecember 2018#\\njanuary 2020#\\n#last usfda inspection ##filing/expected filing\\n during the year, we augmented\\nour ability to file products based\\non technology such as hot\\nmelting extrusion, powder layering\\ntechnology, among others.', 'we are also developing process\\nanalytical tools to enhance\\nthe quality and efficacy\\nof our products.', 'besides complex products, we are\\ndeveloping niche and specialty\\nproducts at our\\n r&d facilities.', 'our r&d pipeline\\ncurrently stands at 200+ products\\nand we expect to file 25-30 new\\nfilings every year.', 'introduction mda strategic review governance and social responsibility statutory reports financial statements\\nannual report 2019-20 35\\nstrategic priorities\\ncustomer-centricity\\nresponding swiftly to newer\\nopportunities\\nin 2019-20, we demonstrated\\nour ability to respond swiftly and\\nefficiently to the emerging needs\\nof our clients.', 'a case in point is the\\nsartans opportunity.', 'as some of\\npeers struggled with issues related\\nto impurity in manufacturing sartans,\\nwe moved quickly to capture the\\nopportunity.', 'our swiftness in\\ndeveloping high-quality products and\\ndelivering them to our customers\\nin a timely manner enables us\\nto gain share.', 'we believe, sartans opportunity will\\nremain strong over the next three to\\nsix months and with 15 andas across\\ndifferent combinations, we are well\\nequipped to maximise its potential.', 'we have been able to capitalise on\\nsuch opportunities consistently,\\nleading to substantial market share\\ngains.', 'our us business registered\\nrobust growth during the year and we\\nare making the requisite investments\\nto fortify it further.', 'strengthening our\\nsupply chain and delivering superior\\ncustomer experience are key focus\\nareas for this business.', 'as supply\\ndisruptions started to correct, our\\ndomestic branded business gathered\\nmomentum in the last quarter of\\n2019-20. this business caters to\\nabout 1,75,000 doctors across 17\\nsegments in india and is ready for a\\nsuccessful turnaround in 2020-21.\\nstrong fundamentals of the\\napi business\\nthe key strengths of our api business\\nare the advanced technology and\\nour high manufacturing expertise.', 'as a consequence, we have become\\none of the preferred suppliers of\\nour customers.', 'this is reflected in\\nour high customer retention and\\nrepeat order levels.', 'over the past\\ntwo to three years, we doubled\\nour api capacity to 1,100 metric\\ntonnes per annum in order to\\nmeet the rising demand.', 'we have\\nimplemented several measures to\\nenhance operational efficiency of this\\nbusiness including automation of our\\nprocesses to reduce contamination.', 'we believe there are immense\\nopportunities in our current apis\\nincluding azithromycin.', 'the api\\nbusiness witnessed softness in\\n2019-20 due to lack of orders from\\na large manufacturing deal with\\nan mnc.', 'the rest of the business\\nwitnessed growth upwards of 20%+in\\nthe year.', 'we believe this business is\\non a solid turf and expect it to grow\\nby atleast 15-20% in 2020-21.\\nour\\ncustomercentric\\nstrategy\\nleverage new\\ncapacities to\\ncapitalise market\\nconditions\\nbuild a\\nstrong products\\npipeline\\nmaintain\\nexecution\\nexcellence\\ncontinue\\nlaunching\\nnew products\\nincrease\\nmarketing\\ngoals and\\nachieve them\\nstrengthen\\nsupply chain\\nwith steady\\nfocus\\n36 alembic pharmaceuticals limited\\ndiversity\\na growing suite of products\\nin a bid to serve our patients better,\\nwe have been focused on developing\\nvaried products for different therapies\\nand across dosage forms.', 'we have\\ncome a long way from being\\nfocused largely on oral solids a few\\nyears back and today offer a wide\\nportfolio of products.', 'our domestic\\nbusiness caters to chronic and acute\\ntherapies including cardiology, antidiabetic, gynaecology, gastrological,\\ndermatological, orthopaedic,\\nophthalmology, nephrology/urology,\\nanti-infective and cold & cough.', 'our\\nofferings in the specialty segment\\nhave been quite successful and we\\nare working to further augment\\nthis portfolio.', 'our diverse team\\nat alembic, our commitment to\\ndrive inclusiveness is reflected in\\nthe diversity of our workforce.', 'our people come from different\\nbackgrounds, skillsets, culture\\nand experiences.', 'together, they\\nempower us to cater to patients\\naround the world with relative\\nease on one hand, and to respond\\nswiftly to their emerging needs,\\non the other.', 'our people culture\\nis based on meritocracy with welldefined rewards and recognitions\\nmechanisms in place.', 'by providing a\\nnurturing environment to our people,\\nwe motivate them to put their best\\nfoot forward, every day']\n"
     ]
    }
   ],
   "source": [
    "# take a random sample from each class and process them\n",
    "with open('Dataset/Final Dataset/Bankrupt/ABGSHIP_2013_MDA.txt', 'r') as file:\n",
    "    md_a_bankrupt = file.read()\n",
    "    processed_bankrupt, sentences = preprocess(md_a_bankrupt)\n",
    "\n",
    "print()\n",
    "\n",
    "with open('Dataset/Final Dataset/Healthy/ALEMBICLTD_2020_MDA.txt', 'r') as file:\n",
    "    md_a_healthy = file.read()\n",
    "    processed_healthy, sentences = preprocess(md_a_healthy)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "\n",
    "### <strong>Sentiment Analysis and Entity Extraction</strong>\n",
    "\n",
    "trying to analyse and plot the ratio of sentiment of a sample of dataset from each class."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Bankrupt Company Sentiment:\n",
      "{'neg': 0.048, 'neu': 0.845, 'pos': 0.106, 'compound': 0.9965}\n",
      "\n",
      "Healthy Company Sentiment:\n",
      "{'neg': 0.029, 'neu': 0.827, 'pos': 0.144, 'compound': 1.0}\n",
      "\n",
      "TextBlob Sentiment Bankrupt Company: Sentiment(polarity=0.08191427581133465, subjectivity=0.3596701609936902)\n",
      "TextBlob Sentiment Healthy Company: Sentiment(polarity=0.1178469986166266, subjectivity=0.4253129062168315)\n"
     ]
    }
   ],
   "source": [
    "from nltk.sentiment import SentimentIntensityAnalyzer\n",
    "from textblob import TextBlob\n",
    "\n",
    "# Sentiment analysis using VADER\n",
    "sia = SentimentIntensityAnalyzer()\n",
    "\n",
    "def analyze_sentiment(text):\n",
    "    sentiment = sia.polarity_scores(text)\n",
    "    return sentiment\n",
    "\n",
    "sentiment_bankrupt = analyze_sentiment(md_a_bankrupt)\n",
    "sentiment_healthy = analyze_sentiment(md_a_healthy)\n",
    "\n",
    "print(\"Bankrupt Company Sentiment:\")\n",
    "print(sentiment_bankrupt)\n",
    "\n",
    "print(\"\\nHealthy Company Sentiment:\")\n",
    "print(sentiment_healthy)\n",
    "\n",
    "# Sentiment analysis using TextBlob (optional)\n",
    "blob_bankrupt = TextBlob(md_a_bankrupt)\n",
    "blob_healthy = TextBlob(md_a_healthy)\n",
    "\n",
    "print()\n",
    "print(\"TextBlob Sentiment Bankrupt Company:\", blob_bankrupt.sentiment)\n",
    "print(\"TextBlob Sentiment Healthy Company:\", blob_healthy.sentiment)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Bankrupt Company Entities:\n",
      "[('ABG Shipyard Limited', 'ORG'), ('2012-2013', 'DATE'), ('28', 'CARDINAL'), ('ABG Shipyard Limited', 'ORG'), ('Corporate Governance', 'ORG'), ('ABG Shipyard Limited', 'ORG'), ('the year ended on 31 March 2013', 'DATE'), ('Clause 49', 'EVENT'), ('the Listing Agreement', 'EVENT'), ('Corporate Governance', 'ORG'), ('Directors', 'PERSON'), ('Company', 'ORG'), ('Clause 49', 'EVENT'), ('Listing Agreement', 'WORK_OF_ART'), ('Company', 'ORG'), ('the \\nManagement', 'ORG'), ('Nisar & Kumar\\n', 'ORG'), ('107117W', 'DATE'), ('M. N. Ahmed\\nPlace', 'PERSON'), ('30', 'CARDINAL'), ('2013', 'DATE'), ('18380', 'DATE'), ('ABG Shipyard Limited', 'ORG'), ('2012-2013', 'DATE'), ('29', 'CARDINAL'), ('Year 2012-13', 'DATE'), ('a challenging year', 'DATE'), ('Indian Economy', 'ORG'), ('4%', 'PERCENT'), ('2011', 'DATE'), ('3.2%', 'PERCENT'), ('2012', 'DATE'), ('5.1%', 'PERCENT'), ('6.4%', 'PERCENT'), ('the previous \\nyear', 'DATE'), ('U.S.', 'GPE'), ('Euro', 'PERSON'), ('0.6%', 'PERCENT'), ('Asian', 'NORP'), ('China', 'GPE'), ('the Financial Year 2012-13', 'EVENT'), ('Indian', 'NORP'), ('about 5', 'CARDINAL'), ('Year-on-year', 'DATE'), ('3  quarter', 'DATE'), ('4.5%', 'PERCENT'), ('second', 'ORDINAL'), ('recent years', 'DATE'), ('around 6%', 'PERCENT'), ('the Financial Year 2013-14', 'DATE'), ('Reserve Bank of India', 'ORG'), ('Indian', 'NORP'), ('Indian', 'NORP'), ('Indian', 'NORP'), ('the previous year', 'DATE'), ('about 24 per cent', 'MONEY'), ('14', 'CARDINAL'), ('2015', 'DATE'), ('the Associate \\nChambers of Commerce', 'ORG'), ('the year', 'DATE'), ('Global Shipbuilding Industry', 'ORG'), ('China', 'GPE'), ('South Korea', 'GPE'), ('Japan', 'GPE'), ('over 80%', 'PERCENT'), ('Chinese Government', 'ORG'), ('35%', 'PERCENT'), ('Chinese', 'NORP'), ('India', 'GPE'), ('Vietnam', 'GPE'), ('2000', 'DATE'), ('India', 'GPE'), ('Korea', 'GPE'), ('China', 'GPE'), ('Indian', 'NORP'), ('less than 1 percent', 'PERCENT'), ('Shipyards \\nAssociation of India', 'ORG'), ('SAI', 'ORG'), ('China', 'GPE'), ('South Korea', 'GPE'), ('Japan', 'GPE'), ('more than 80', 'CARDINAL'), ('The Indian Shipbuilding and Ship repair Industry', 'ORG'), ('9,200', 'CARDINAL'), ('year \\n2015', 'DATE'), ('about 8 per cent', 'MONEY'), ('India', 'GPE'), ('20', 'CARDINAL'), ('a year', 'DATE'), ('70', 'DATE'), ('a year', 'DATE'), ('almost 90%', 'PERCENT'), ('8,000 kilometer', 'QUANTITY'), ('about 27', 'CARDINAL'), ('12', 'CARDINAL'), ('200', 'CARDINAL'), ('India', 'GPE'), ('Approximately 90%', 'PERCENT'), ('70%', 'PERCENT'), ('Maritime Transport', 'ORG'), ('` 800 billion', 'MONEY'), ('3300.00 billion', 'MONEY'), ('0.4 million', 'CARDINAL'), ('around 2.4 \\nmillion', 'QUANTITY'), ('The Indian Government', 'ORG'), ('Government', 'ORG'), ('the Shipbuilding Subsidy Scheme', 'ORG'), ('2002', 'DATE'), ('2007', 'DATE'), ('Industrial Bodies', 'ORG'), ('Indian', 'NORP'), ('2.4 million', 'CARDINAL'), ('100%', 'PERCENT'), ('FDI', 'ORG'), ('OPPORTUNITIES & THREATS\\nUnion', 'ORG'), ('2013-14', 'DATE'), ('6%', 'PERCENT')]\n",
      "\n",
      "Healthy Company Entities:\n",
      "[('US', 'GPE'), ('five years ago', 'DATE'), ('10-12', 'CARDINAL'), ('US', 'GPE'), ('over $250 million', 'MONEY'), ('the past five years', 'DATE'), ('US', 'GPE'), ('Sartans', 'NORP'), ('2019-20', 'DATE'), ('US Generics', 'ORG'), ('FY18', 'ORG'), ('1,228', 'CARDINAL'), ('9201,288 1,976', 'CARDINAL'), ('Oncology Injectable and', 'ORG'), ('Governance', 'PERSON'), ('Statutory reports Financial', 'ORG'), ('Annual Report', 'WORK_OF_ART'), ('Concentrated', 'ORG'), ('10', 'CARDINAL'), ('18', 'CARDINAL'), ('Alembic Pharmaceuticals Limited', 'ORG'), ('the past few years', 'DATE'), ('Venlafaxine', 'ORG'), ('Azithromycin', 'PERSON'), ('India', 'GPE'), ('Azithromycin', 'GPE'), ('30%', 'PERCENT'), ('India', 'GPE'), ('Azithromycin', 'PERSON'), ('Azithromycin', 'PERSON'), ('US', 'GPE'), ('Europe', 'LOC'), ('USFDA', 'ORG'), ('Azithromycin', 'PERSON'), ('US', 'GPE'), ('January 2020', 'DATE'), ('US', 'GPE'), ('Azithromycin', 'PERSON'), ('$129 million', 'MONEY'), ('12 months ended September 2019', 'DATE'), ('Formulation Plant', 'ORG'), ('Panelav', 'PERSON'), ('Governance', 'PERSON'), ('Statutory reports Financial', 'ORG'), ('Annual Report', 'WORK_OF_ART'), ('25', 'CARDINAL'), ('483â€', 'CARDINAL'), ('years', 'DATE'), ('20', 'CARDINAL'), ('Alembic Pharmaceuticals Limited', 'ORG'), ('every day', 'DATE'), ('US', 'GPE'), ('the years', 'DATE'), ('India', 'GPE'), ('the years', 'DATE'), ('about 11,500', 'CARDINAL'), ('the past five years', 'DATE'), ('one', 'CARDINAL'), ('below 1x', 'CARDINAL'), ('Indian', 'NORP'), ('USFDA', 'ORG'), ('Aleor', 'PERSON'), ('zero', 'CARDINAL'), ('F1', 'GPE'), ('Governance', 'PERSON'), ('Statutory reports Financial', 'ORG'), ('Annual Report', 'WORK_OF_ART'), ('2019-20 21', 'DATE'), ('Today', 'DATE'), ('Tomorrow', 'DATE'), ('22', 'CARDINAL'), ('Alembic Pharmaceuticals Limited\\nOur', 'ORG'), ('today', 'DATE'), ('today', 'DATE'), ('tomorrow', 'DATE'), ('Alembic', 'GPE'), ('One', 'CARDINAL'), ('US', 'GPE'), ('less than five years', 'DATE'), ('US', 'GPE'), ('Indian', 'NORP'), ('US', 'GPE'), ('US', 'GPE'), ('General Injectable and Ophthalmic Plant', 'ORG'), ('Governance', 'PERSON'), ('Statutory reports Financial', 'ORG'), ('Annual Report', 'WORK_OF_ART'), ('USA', 'GPE'), ('Canada', 'GPE'), ('Europe', 'LOC'), ('Australia', 'GPE'), ('South\\nAfrica', 'GPE'), ('Brazil', 'GPE'), ('recent\\nyears', 'DATE'), ('2019-20', 'DATE'), ('54%', 'PERCENT'), ('the year', 'DATE'), ('39%', 'PERCENT'), ('2,473', 'CARDINAL'), ('1,782', 'CARDINAL'), ('2018-19', 'DATE'), ('US', 'GPE'), ('1,976', 'CARDINAL'), ('the\\nyear', 'DATE'), ('43%', 'PERCENT'), ('80%', 'PERCENT'), ('US', 'GPE'), ('53%', 'PERCENT'), ('1,288', 'CARDINAL'), ('2018-19', 'DATE'), ('US', 'GPE'), ('the year', 'DATE'), ('497', 'CARDINAL'), ('494', 'CARDINAL'), ('2018-19', 'DATE'), ('the year', 'DATE'), ('Aleor', 'PERSON'), ('Karkhadi', 'PRODUCT'), ('USFDA', 'ORG'), ('F1', 'GPE'), ('Panelav', 'PERSON'), ('four', 'CARDINAL'), ('USFDA', 'ORG'), ('22', 'CARDINAL'), ('US', 'GPE'), ('nine', 'CARDINAL'), ('2018-19', 'DATE'), ('New Oral Solid Plant', 'ORG'), ('24', 'CARDINAL'), ('Alembic Pharmaceuticals Limited\\nUpdate', 'ORG'), ('Rhizen\\nPharmaceuticals\\n Rhizen Pharmaceuticals SA', 'ORG'), ('50%', 'PERCENT'), ('2020-21', 'DATE'), ('first', 'ORDINAL'), ('the year', 'DATE'), ('Rhizen', 'PERSON'), ('Umbralisib', 'GPE'), ('TG Therapeutics', 'ORG'), ('September 2014', 'DATE'), ('NDA', 'ORG'), ('Umbralisib', 'GPE'), ('MZL', 'ORG'), ('Follicular Lymphoma', 'ORG'), ('2020-21', 'DATE'), ('3', 'CARDINAL'), ('Umbralisib', 'PERSON'), ('CLL', 'ORG'), ('2020-21', 'DATE'), ('API 1', 'PRODUCT'), ('Panelav', 'PERSON'), ('FY18', 'ORG'), ('1,461', 'CARDINAL'), ('2,473', 'CARDINAL'), ('Rhizen Pharmaceuticals', 'PERSON'), ('Governance', 'PERSON'), ('Statutory reports Financial', 'ORG'), ('Annual Report', 'WORK_OF_ART'), ('nephro / uro', 'ORG'), ('cold & cough', 'ORG'), ('2019-20', 'DATE'), ('31%', 'PERCENT'), ('3%', 'PERCENT'), ('1,425', 'CARDINAL'), ('1,382', 'CARDINAL'), ('2018-19', 'DATE'), ('65%', 'PERCENT'), ('93%', 'PERCENT'), ('the last five years', 'DATE'), ('2020-21', 'DATE'), ('MR', 'GPE'), ('2020-21', 'DATE'), ('the past three quarters', 'DATE'), ('the end of 2018-19', 'DATE'), ('last quarter', 'DATE'), ('2020-21', 'DATE'), ('Research and Development Center', 'ORG'), ('26', 'CARDINAL'), ('Alembic Pharmaceuticals Limited\\nFormulation Plant', 'ORG'), ('India', 'GPE'), ('National List of Essential Medicines', 'ORG'), ('NLEM', 'ORG'), ('Indian', 'NORP'), ('FY18', 'ORG'), ('1,176', 'CARDINAL'), ('1,255', 'CARDINAL'), ('1,382 1,425', 'CARDINAL'), ('Governance', 'PERSON'), ('Statutory reports Financial', 'ORG'), ('Annual Report', 'WORK_OF_ART'), ('the\\nfull year', 'DATE'), ('4,606', 'CARDINAL'), ('17%', 'PERCENT'), ('3,935', 'CARDINAL'), ('10-year', 'DATE'), ('15%', 'PERCENT'), ('Consolidated PAT', 'ORG'), ('42%', 'PERCENT'), ('829', 'CARDINAL'), ('584', 'CARDINAL'), ('10-year', 'DATE'), ('PAT', 'ORG'), ('36%', 'PERCENT'), ('10-year', 'DATE'), ('26%', 'PERCENT'), ('1,213', 'CARDINAL'), ('875', 'CARDINAL'), ('March\\n31, 2020', 'DATE'), ('10,071.46', 'CARDINAL'), ('7.0', 'CARDINAL'), ('3.0', 'CARDINAL'), ('500%', 'PERCENT'), ('2', 'CARDINAL'), ('2018-19', 'DATE'), ('5.5', 'CARDINAL'), ('275%', 'PERCENT'), ('2019-20', 'DATE'), ('a remarkable year', 'DATE'), ('US', 'GPE'), ('697', 'CARDINAL'), ('2019-20', 'DATE'), ('2020-21', 'DATE'), ('700', 'CARDINAL'), ('2021-22', 'DATE'), ('300', 'CARDINAL'), ('up to 0.52x', 'CARDINAL'), ('2019-20', 'DATE'), ('0.34x', 'CARDINAL'), ('2018-19', 'DATE'), ('2021-22', 'DATE'), ('Research and Development Center', 'ORG'), ('New Jersey', 'GPE'), ('28', 'CARDINAL'), ('Alembic Pharmaceuticals Limited\\nCFOâ€', 'ORG'), ('US', 'GPE'), ('2019-20', 'DATE'), ('the end of the year', 'DATE'), ('first', 'ORDINAL'), ('three\\nquarters', 'CARDINAL'), ('non-US', 'NORP'), ('the year', 'DATE'), ('US', 'GPE'), ('three', 'CARDINAL'), ('four years', 'DATE'), ('2020-21', 'DATE'), ('CRISIL', 'ORG'), ('A1+', 'DATE'), ('Kumar Baheti', 'PERSON'), ('CFO', 'ORG'), ('Governance', 'PERSON'), ('Statutory reports Financial', 'ORG'), ('Annual Report', 'WORK_OF_ART'), ('Regulatory & Compliance', 'ORG'), ('Indian', 'NORP'), ('24x7', 'CARDINAL'), ('30', 'CARDINAL'), ('Alembic Pharmaceuticals Limited\\nTemporary', 'ORG'), ('companyâ€', 'ORG'), ('IPR\\ndepartment', 'ORG'), ('Ernst & Young', 'ORG'), ('the Risk\\nManagement Committee', 'ORG'), ('the\\nBoard of Directors', 'ORG'), ('Company', 'ORG'), ('ISO 9001', 'PRODUCT'), ('ISO 14001', 'PRODUCT'), ('Introduction MDA Strategic', 'PRODUCT'), ('Governance', 'PERSON'), ('Statutory reports Financial', 'ORG'), ('Annual Report', 'WORK_OF_ART'), ('IMF', 'ORG'), ('2.9%', 'PERCENT'), ('2019', 'DATE'), ('70', 'CARDINAL'), ('2018', 'DATE'), ('2020', 'DATE'), ('IMF', 'ORG'), ('3%', 'PERCENT'), ('2020', 'DATE'), ('Indian', 'NORP'), ('IMF', 'ORG'), ('Indian', 'NORP'), ('1.9%', 'PERCENT'), ('2021', 'DATE'), ('5.8%', 'PERCENT'), ('Indian', 'NORP'), ('7.4%', 'PERCENT'), ('3.6', 'CARDINAL'), ('2.9', 'CARDINAL'), ('5.8', 'CARDINAL'), ('2018', 'DATE'), ('2020', 'DATE'), ('2021', 'DATE'), ('2018', 'DATE'), ('April 2020', 'DATE'), ('32', 'CARDINAL'), ('Alembic Pharmaceuticals Limited\\nDemographic', 'ORG'), ('7.8 Billion', 'CARDINAL'), ('May 2020', 'DATE'), ('8.5 Billion', 'CARDINAL'), ('2030', 'DATE'), ('9.7 Billion', 'CARDINAL'), ('2050', 'DATE'), ('United\\nNations', 'ORG'), ('Africa', 'LOC'), ('Asia', 'LOC'), ('second', 'ORDINAL'), ('China', 'GPE'), ('India', 'GPE'), ('80', 'DATE'), ('over\\nthree', 'CARDINAL'), ('425 Million', 'CARDINAL'), ('2050', 'DATE'), ('EU', 'ORG'), ('February\\n2019', 'DATE'), ('EU', 'ORG'), ('2019-20', 'DATE'), ('the past few years', 'DATE'), ('India', 'GPE'), ('851', 'CARDINAL'), ('National List of Essential\\nMedicines', 'ORG'), ('2015', 'DATE'), ('5.3', 'CARDINAL'), ('7.3 8.5', 'CARDINAL'), ('11.2', 'CARDINAL'), ('1990', 'DATE'), ('2050', 'DATE'), ('2030', 'DATE'), ('2015', 'DATE'), ('Governance', 'PERSON'), ('Statutory reports Financial', 'ORG'), ('Annual Report', 'WORK_OF_ART'), ('four', 'CARDINAL'), ('two', 'CARDINAL'), ('Good Manufacturing\\nPractices', 'ORG'), ('GMP', 'ORG'), ('National Science\\nFoundation', 'ORG'), ('NSF', 'ORG'), ('the past few years', 'DATE'), ('recent years', 'DATE'), ('Laboratory Information\\nManagement System', 'ORG'), ('34', 'CARDINAL'), ('Alembic Pharmaceuticals Limited\\nCapability', 'ORG'), ('2,000', 'CARDINAL'), ('2020-21', 'DATE'), ('US', 'GPE'), ('2021-22', 'DATE'), ('about 1,200', 'CARDINAL'), ('6.7%', 'PERCENT'), ('2014-15', 'DATE'), ('14%', 'PERCENT'), ('2019-20', 'DATE'), ('90%', 'PERCENT'), ('US', 'GPE'), ('US', 'GPE'), ('contararian', 'NORP'), ('Para IV', 'PRODUCT'), ('2021-22', 'DATE'), ('Audit/Filing', 'ORG'), ('API\\nF1-Panelav\\nF2-Panelav\\nF3-Karkhadi\\nF4-Jarod\\nAleor (JV) Karkhadi\\nAPI I & II-Panelav\\nAPI III-Karkhadi\\nGeneral', 'ORG'), ('March 2020', 'DATE'), ('June 2019', 'DATE'), ('#\\nH2FY21##\\n', 'MONEY'), ('January 2020', 'DATE'), ('January 2020', 'DATE'), ('December 2018', 'DATE'), ('January 2020', 'DATE'), ('#\\n#', 'MONEY'), ('the year', 'DATE'), ('200+', 'DATE'), ('25-30', 'CARDINAL'), ('every year', 'DATE'), ('Governance', 'PERSON'), ('Statutory reports Financial', 'ORG'), ('Annual Report', 'WORK_OF_ART'), ('2019-20', 'DATE'), ('the next three to\\n', 'DATE'), ('six months', 'DATE'), ('15', 'CARDINAL'), ('US', 'GPE'), ('the year', 'DATE'), ('the last quarter', 'DATE'), ('2019-20', 'DATE'), ('about 1,75,000', 'CARDINAL'), ('17', 'CARDINAL'), ('India', 'GPE'), ('2020-21', 'DATE'), ('API', 'ORG'), ('API', 'ORG'), ('the past\\n', 'DATE'), ('two to three years', 'DATE'), ('API', 'ORG'), ('1,100 metric\\ntonnes', 'QUANTITY'), ('Azithromycin', 'PERSON'), ('API', 'ORG'), ('2019-20', 'DATE'), ('MNC', 'ORG'), ('20%+in', 'CARDINAL'), ('the year', 'DATE'), ('15-20%', 'PERCENT'), ('2020-21', 'DATE'), ('36', 'CARDINAL'), ('Alembic Pharmaceuticals Limited\\nDiversity', 'ORG'), ('a few\\nyears back', 'DATE'), ('today', 'DATE'), ('cold & cough', 'ORG'), ('every day', 'DATE')]\n"
     ]
    }
   ],
   "source": [
    "def extract_entities(text):\n",
    "    doc = nlp(text)\n",
    "    entities = [(ent.text, ent.label_) for ent in doc.ents]\n",
    "    return entities\n",
    "\n",
    "entities_bankrupt = extract_entities(md_a_bankrupt)\n",
    "entities_healthy = extract_entities(md_a_healthy)\n",
    "\n",
    "print(\"Bankrupt Company Entities:\")\n",
    "print(entities_bankrupt)\n",
    "\n",
    "print(\"\\nHealthy Company Entities:\")\n",
    "print(entities_healthy)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot the scores\n",
    "\n",
    "labels = ['neg', 'neu', 'pos']\n",
    "bankrupt_scores = [sentiment_bankrupt[label] for label in labels]\n",
    "healthy_scores = [sentiment_healthy[label] for label in labels]\n",
    "\n",
    "x = range(len(labels))\n",
    "plt.bar(x, bankrupt_scores, width=0.4, label='Bankrupt', align='center')\n",
    "plt.bar(x, healthy_scores, width=0.4, label='Healthy', align='edge')\n",
    "plt.xticks(x, labels)\n",
    "plt.legend()\n",
    "plt.show()\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
